PDS Biotechnology receives Nasdaq deficiency notice for bid price below $1.00

PDS Biotechnology Corp

Received deficiency letter on July 30, 2026 for failing to meet minimum bid price of $1.00 for 30 consecutive business days.
Has 180 calendar days, until January 26, 2027, to regain compliance with Nasdaq Listing Rule 5550(a)(2).
Compliance can be regained if closing bid price is at least $1.00 for 10 consecutive business days during the period.
Company may consider a reverse stock split to cure the deficiency; no assurance of regaining compliance.
If not cured by deadline, stock may be delisted; company can appeal a delisting determination to a hearings panel.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.